首页> 外文期刊>Molecular therapy: the journal of the American Society of Gene Therapy >Induced Apoptosis Investigation in Wild-type and FLT3-ITD Acute Myeloid Leukemia Cells by Nanochannel Electroporation and Single-cell qRT-PCR
【24h】

Induced Apoptosis Investigation in Wild-type and FLT3-ITD Acute Myeloid Leukemia Cells by Nanochannel Electroporation and Single-cell qRT-PCR

机译:纳米通道电穿孔和单细胞qRT-PCR诱导野生型和FLT3-ITD急性髓细胞白血病细胞凋亡的研究。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Nanochannel electroporation (NEP) was applied to deliver precise dosages of myeloid cell leukemia-1 (Mcl-1)-specific siRNA and molecular beacons to two types of acute myeloid leukemia (AML) cells, FMS-like tyrosine kinase-3 wild-type (WT) and internal tandem duplications (ITD) type at the single-cell level. NEP, together with single-cell quantitative reverse transcription PCR, led to an observation showing nearly 20-folds more Mcl-1 siRNA than MCL1 mRNA were required to induce cell death for both cell lines and patient blasts, i.e., similar to 8,800 siRNAs for similar to 500 +/- 50 mRNAs in ITD cells and similar to 6,000 siRNAs for similar to 300 +/- 50 mRNAs in WT cells. A time-lapse study revealed that >75% MCL1 mRNA was down-regulated within 1 hour after delivery of a small amount of siRNA. However, additional siRNA was required to inhibit the newly transcribed mRNA for >12 hours until the cell lost its ability of self-protection recovery. A multidelivery strategy of low doses and short delivery interval, which require 77% less siRNA and has the potential of lower side effects and clinical cost, was as effective as a single high-dose siRNA delivery. Our method provides a viable analytical tool to investigate gene silencing at the single-cell level for oligonucleotide-based therapy.
机译:纳米通道电穿孔(NEP)用于向两种类型的急性髓性白血病(AML)细胞(FMS样酪氨酸激酶3野生型)提供精确剂量的髓样细胞白血病1(Mcl-1)特异性siRNA和分子信标。 (WT)和内部串联重复(ITD)类型在单单元级别。 NEP与单细胞定量逆转录PCR一起导致的观察结果表明,诱导细胞系和患者胚细胞死亡所需的Mcl-1 siRNA比MCL1 mRNA多出近20倍,即与8800 siRNA相似。与ITD细胞中的500 +/- 50 mRNA相似,与WT细胞中的300 +/- 50 mRNA相似,与6,000 siRNA相似。一项延时研究显示,在递送少量siRNA后1小时内,> 75%的MCL1 mRNA被下调。但是,需要额外的siRNA抑制新转录的mRNA超过12小时,直到细胞丧失其自我保护恢复能力。低剂量和短递送间隔的多递送策略,其所需的siRNA减少了77%,并且具有降低副作用和降低临床成本的潜力,其效果与单次大剂量siRNA递送一样有效。我们的方法提供了一种可行的分析工具,用于研究基于寡核苷酸的治疗在单细胞水平上的基因沉默。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号